VIR-2482 (Dose 1) for influenza A virus

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
influenza A virus+1 More
VIR-2482 (dose 1) - Biological
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to <65 years of age without pre-existing risk factors for serious complications from influenza infection.

Eligible Conditions
  • influenza A virus

Treatment Effectiveness

Study Objectives

6 Primary · 2 Secondary · Reporting Duration: Up to Week 84

Up to Week 84
Occurrence of adverse events (AEs)
Occurrence of adverse events of special interest (AESI)
Occurrence of serious adverse events (SAEs)
Percentage of Participants with Abnormalities in Vital Signs
Percentage of Participants with Clinically significant Abnormalities in Clinical Laboratory Tests
Proportion of participants with CDC-defined ILI with confirmed influenza A (by RT-PCR)
Proportion of participants with WHO-defined ILI with confirmed influenza A (by RT-PCR)
Proportion of participants with protocol-defined ILI with confirmed influenza A (by reverse transcription-polymerase chain reaction [RT-PCR])

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

VIR-2482 (Dose 1)
1 of 3
VIR-2482 (Dose 2)
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

3000 Total Participants · 3 Treatment Groups

Primary Treatment: VIR-2482 (Dose 1) · Has Placebo Group · Phase 2

VIR-2482 (Dose 1)
Biological
Experimental Group · 1 Intervention: VIR-2482 (dose 1) · Intervention Types: Biological
VIR-2482 (Dose 2)
Biological
Experimental Group · 1 Intervention: VIR-2482 (dose 2) · Intervention Types: Biological
Placebo
Biological
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 84

Who is running the clinical trial?

Vir Biotechnology, Inc.Lead Sponsor
23 Previous Clinical Trials
9,930 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are between the ages of 18 and 65 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: November 23rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Kentucky50.0%
Indiana50.0%
What site did they apply to?
Investigative Site100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?
0100.0%
Why did patients apply to this trial?
  • "I’m interested in participating in clinical trials"